Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.

Published on Aug 28, 2021in The New England Journal of Medicine74.699
· DOI :10.1056/NEJMOA2110956
Peter Kolkhof11
Estimated H-index: 11
Abstract Background Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 chronic kid...
📖 Papers frequently viewed together
190 Citations
1 Citations
9 Citations
Cited By6
#1Pierre Delanaye (University of Liège)H-Index: 49
#2André Scheen (University of Liège)H-Index: 93
Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) are new oral glucose-lowering agents that provide cardiovascular and renal protection in both patients with and without type 2 diabetes. Because of their unique mechanism of action, increased glucosuria is associated with osmotic diuresis and some natriuresis, yet the latter seems mostly transient. The potential role of the diuretic effect in overall cardiovascular and renal protection by SGLT2is remains a matter of debate. Precise evaluat...
1 CitationsSource
#1Peter Kolkhof (Bayer)H-Index: 10
#2Amer Joseph (Bayer)H-Index: 5
Last. Ulrich Kintscher (Charité)H-Index: 44
view all 3 authors...
Abstract null null During the recent 30 years, there has been a dramatic increase in knowledge about the role of aldosterone and the mineralocorticoid receptor (MR) in the pathophysiology of cardiovascular (CV) and kidney diseases. The scientific perspective on the aldosterone/MR ensemble extended from a previously renal epithelial-centered focus on sodium-potassium exchange to a broader view as systemic modulators of extracellular matrix, inflammation and fibrosis. Spironolactone was launched a...